Please login to the form below
Biogen expands digital safety platform Assessa
The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting
Biogen has expanded work on its digital safety platform, which helps monitor MS patients for signs of the rare and potentially fatel brain infection progressive multifocal leukoencephalopathy (PML).
The pilot programme, a collaboration with tech firm Ixico, will now include pharmacoviglance reporting to monitor patients for previously unreported adverse reactions.
The partners - who have been in a collaborative agreement since October 2015 - developed the Assessa system to provide neurologists with second opinion reading services if there is a suspicion of PML.
Giulio Cerroni, chief executive officer of Ixico, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen.
“The Assessa PML digital platform is intended to provide technology and speciality services to physcians involved in delivering care to people living with MS.”
Biogen has invested £1.5m in the project, which is currently being piloted in five EU countries.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Sinopharm’s COVID-19 vaccine scores approval in China
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
